Sustained activation of extracellular signal-regulated kinase (ERK) signaling in human prostate cancer LNCaP cells depleted of androgen

Prostate Journal

Volumn 3, Issue 2, 2001, Pages 105-117

  Drew, Lisa ^a   Fine, Robert L ^a   Raffo, Anthony J ^a   Petrylak, Daniel P ^a  

^a Department of Orthopaedic Surgery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANDROGEN; ANDROSTANOLONE; FINASTERIDE; MIBOLERONE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN ERB B; PROTEIN ERB B3; PROTEIN ERB B4; STEROID; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ANDROGEN SYNTHESIS; ARTICLE; CANCER CELL; CELL CULTURE; CELL DIFFERENTIATION; CELL GROWTH; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; INCUBATION TIME; MITOSIS INHIBITION; NERVE CELL; NEURITE; NEUROENDOCRINE SYSTEM; PRIORITY JOURNAL; PROSTATE CARCINOMA; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

EID: 0035715108     PISSN: 10955100     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1411.2001.32003.x     Document Type: Article

References (62)

1. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer
2. Antagonistic effect of androgen on prostatic cell death
3. Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer
4. Androgen metabolism and prostate cancer: Establishing a model of genetic susceptibility
5. Endocrine control of prostate cancer
6. Neuroendocrine differentiation and hormone-refactory prostate cancer
7. Neuroendocrine differentiation in prostate cancer: Enhanced prediction of progression after radical prostatectomy
8. Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment
9. Signal transduction through MAP kinase cascades
10. Mitogen-activated protein kinase cascades as regulators of stress responses
11. Signaling from G-protein-coupled receptors to mitogen-activated protein (MAP)-kinase cascades
12. Growth factor signaling by receptor tyrosine kinases
13. Elevated mitogen-activated protein kinase activity in estrogen- nonresponsive human breast cancer cells
14. The complexity of Raf-1 regulation
15. Interactions between ras and raf: Key regulatory proteins in cellular transformation
16. The MAPK signaling cascade
17. Raf meets ras: Completing the framework of a signal transduction pathway
18. Activation of MAP kinase kinase is necessary and sufficient for PC 12 differentiation and for transformation of NIH 3T3 cells
19. Activation of mitogen-activated protein kinase associated with prostate cancer progression
20. Raf-1 causes growth suppression and alteration of neuroendocrine markers in DMS53 human small-cell lung cancer cells
21. Raf-1-induced cell cycle arrest in LNCaP human prostate cancer cells
22. Regulation of heregulin beta1-induced differentiation in a human breast carcinoma cell line by the extracellular-regulated kinase (ERK) pathway
23. EGF triggers neuronal differentiation of PC12 cells that overexpress the EGF receptor
24. Activated Raf-1 causes growth arrest in human small cell lung cancer cells
25. TrkB/insulin receptor-related receptor chimeric receptor induces PC12 cell differentiation and exhibits prolonged activation of mitogen-activated protein kinase
26. Expression of the activated p185erbB2 tyrosine kinase in human epithelial cells leads to MAP kinase activation but does not oncogenicity
27. Insertion of the v-Ha-ras oncogene induces differentiation of calcitonin-producing human small cell lung cancer
28. Introduction of v-Ha-ras oncogene induces differentiation of cultured human medullary thyroid carcinoma cells
29. Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation
30. Signaling specificity: The RTK/RAS/MAP kinase pathway in metazoans
31. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol- receptor complex in MCF-7 cells
32. Estrogen activates raf-1 kinase and induces expression of Egr-1 in MCF-7 breast cancer cells
33. Rapid signaling by androgen receptor in prostate cancer cells
34. Apoptotic program is initiated but not completed in LNCaP cells in response to growth in charcoal-stripped media
35. Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells
36. Transdifferentiation of cultured human prostate cancer cells to a neuroendocrine cell phenotype in a hormone-depleted medium
37. Negative controls of cell proliferation: Human prostate cancer cells and androgens
38. Application of the MTT assay to human prostate cancer cell lines in vitro: Establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostatic and cytotoxic effects
39. Intracellular expression of single chain antibodies reverts ErbB-2 transformation
40. Effect of culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaP
41. Elevation of cyclic adenosine 3′,5′-monophosphate potentiates activation of mitogen-activated protein kinase by growth factors in LNCaP prostate cancer cells
42. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines
43. Finasteride: The first 5 alpha-reductase inhibitor
44. Finasteride dose-dependently reduces the proliferation rate of the LnCap human prostatic cancer cell line in vitro
45. Identification of a novel inhibitor of mitogen-activated protein kinase kinase
46. Inhibition of mitogen-activated protein kinase kinase blocks T cell proliferation but does not induce or prevent anergy
47. The erbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions
48. ErbB-2, the preferred heterodimerization partner of all erbB receptors, is a mediator of lateral signaling
49. The effects of dihydrotestosterone on the expression of p185erbB-2 and cerbB-2 mRNA in the prostatic call line LNCaP
50. ErbB kinases and NDF signaling in human prostate cancer cells
51. Antiapoptotic signaling in LNCaP prostate cancer cells: A survival signaling pathway independent of phosphatidylinositol 3′-kinase and Akt/protein kinase B
52. Interleukin-6 induces G1 arrest through induction of p27, a cyclic-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells
53. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: Implications for prostate cancer progression
54. Growth regulation and cellular changes during differentiation of human prostatic cancer LNCaP cells as induced by T lymphocyte-conditioned medium
55. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo
56. An intron 1 enhancer element mediates oestrogen-induced suppression of ErbB2 expression
57. Rapid turnover of the platelet-derived growth factor receptor in sis-transformed cells and reversal by suramin
58. Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation
59. Hormonal regulation of transforming growth factor beta-2 expression in human prostate cancer
60. Transforming growth factor-beta signaling in epithelial cells
61. From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells
62. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase